BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» Corixa, GSK Win FDA Approval Of Bexxar In Cancer Indication
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Corixa, GSK Win FDA Approval Of Bexxar In Cancer Indication
July 1, 2003
By
Kim Coghill
No Comments
After a difficult journey through the FDA's regulatory process, Corixa Corp. and partner GlaxoSmithKline plc Monday received approval for Bexxar, a radioimmunotherapy for the treatment of patients with non-Hodgkin's lymphoma. (BioWorld Today)
BioWorld